Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.
Revenue of Faes Farma, S.A. (FAE.MC)
Revenue in 2023 (TTM): $488.16 M
According to Faes Farma, S.A.'s latest financial reports the company's current revenue (TTM) is $488.16 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Faes Farma, S.A.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $488.16 M | $321.48 M | $133.37 M | $111.29 M | $99.44 M |
| 2022 | $474.73 M | $305.14 M | $131.46 M | $109.74 M | $96.83 M |
| 2021 | $431.24 M | $273.09 M | $124.08 M | $101.69 M | $89.15 M |
| 2020 | $411.42 M | $259.5 M | $114.27 M | $91.84 M | $78.5 M |
| 2019 | $386.7 M | $246.06 M | $98.99 M | $80.26 M | $69.21 M |
| 2018 | $350.9 M | $220.87 M | $78.56 M | $66.79 M | $55.82 M |
| 2017 | $297.09 M | $192.75 M | $61.44 M | $54.67 M | $45.68 M |
| 2016 | $247.38 M | $163.59 M | $58.03 M | $49.84 M | $39.59 M |
| 2015 | $221.51 M | $144.74 M | $51.51 M | $42.45 M | $32.85 M |
| 2014 | $207.46 M | $136.37 M | $46.05 M | $35.44 M | $27.41 M |
| 2013 | $195.19 M | $124.05 M | $39.25 M | $26.18 M | $24.46 M |
| 2012 | $190.55 M | $122.33 M | $33.75 M | $20.83 M | $21.12 M |
| 2011 | $205.82 M | $125.4 M | $25.94 M | $13.4 M | $15.34 M |
| 2010 | $219.11 M | $128.29 M | $34.97 M | $21.05 M | $21.64 M |
| 2009 | $142.18 M | $141.27 M | $21.33 M | $12.9 M | $19.65 M |
| 2008 | $210.1 M | $124.32 M | $38.44 M | $19.43 M | $21.22 M |
| 2007 | $201.19 M | $124.82 M | $39.03 M | $20.43 M | $23.97 M |
| 2006 | $200.37 M | $200.37 M | $24.5 M | $23.52 M | $24.64 M |
| 2005 | $180.1 M | $180.1 M | $24.62 M | $21.78 M | $25.18 M |
| 2004 | $176.37 M | $112.97 M | $51.49 M | $29.08 M | $25.74 M |
| 2003 | $187.56 M | $121.22 M | $43.78 M | $24.3 M | $21.14 M |